The novel potential biomarkers for multidrug-resistance tuberculosis using UPLC-Q-TOF-MS

Abstract

The lack of rapid and efficient diagnostics impedes largely the epidemic control of multidrug-resistant tuberculosis, and might misguide the therapeutic strategies as well. This study aimed to identify novel multidrug-resistant tuberculosis biomarkers to improve the early intervention, symptomatic treatment and control of the prevalence of multidrug-resistant tuberculosis. The serum small molecule metabolites in healthy controls, patients with drug-susceptible tuberculosis, and patients with multidrug-resistant tuberculosis were screened using ultra-high-performance liquid chromatography combined with quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS). The differentially abundant metabolites were filtered out through multidimensional statistical analysis and bioinformatics analysis. Compared with drug-susceptible tuberculosis patients and healthy controls, the levels of 13 metabolites in multidrug-resistant tuberculosis patients altered. Among them, the most significant changes were found in N1-Methyl-2-pyridone-5-carboxamide (N1M2P5C), 1-Myristoyl-sn-glycerol-3-phosphocholine (MG3P), Caprylic acid (CA), and D-Xylulose (DX). And a multidrug-resistant tuberculosis/drug-susceptible tuberculosis differential diagnostic model was built based on these four metabolites, achieved the accuracy, sensitivity, and specificity of 0.928, 86.7%, and 86.7%, respectively. The enrichment analysis of metabolic pathways showed that the phospholipid remodeling of cell membranes was active in multidrug-resistant tuberculosis patients. In addition, in patients with tuberculosis, the metabolites of dipalmitoyl phosphatidylcholine (DPPC), a major component of pulmonary surfactant, were down-regulated. N1M2P5C, MG3P, CA, and DX may have the potential to serve as novel multidrug-resistant tuberculosis biomarkers. This research provides a preliminary experimental basis to further investigate potential multidrug-resistant tuberculosis biomarkers. Impact statement The MDR-TB incidence remains high, making the effective control of TB epidemic yet challenging. Rapid and accurate diagnosis is vitally important for improving the therapeutic efficacy and controlling the prevalence of drug resistance TB. Metabolomics has dramatic potential to distinguish MDR-TB and DS-TB. N1M2P5C, MG3P, CA, and DX that we identified in this study might have potential as novel MDR-TB biomarkers. The phospholipid remodeling of cell membranes was highly active in MDR-TB. The DPPC metabolites in TB were significantly down-regulated. This work aimed to investigate potential MDR-TB biomarkers to enhance the clinical diagnostic efficacy. The metabolic pathway distinctly altered in MDR-TB might provide novel targets to develop new anti-TB drugs.

Novel Potential Diagnostic Serum Biomarkers of Metabolomics in Osteoarticular Tuberculosis Patients: A Preliminary Study

“…Moreover, it also reported increased eicosanoid ratios in plasma in tuberculosis patients compared to healthy control (Mayer-Barber and Sher, 2015). However, related research about the lipid in osteoarticular tuberculosis or even other extrapulmonary tuberculosis is rare; the results of our research, whether from the differential metabolites screened out or the signal pathways obtained from bioinformatics, are closely related to the results of pulmonary tuberculosis-related research (Huang et al, 2020;Han et al, 2021). It provides more reference value for future research on diagnostic biomarkers from the perspective of metabolomics and provides some hints for the establishment of subsequent auxiliary diagnostic methods for these differential metabolites.…”

Metabolomics as a Tool to Investigate HIV/TB Co-Infection

“…Interestingly, these lipids were restored after 1 year of ART ( Peltenburg et al, 2018 ). Huang et al (2020) searched for serum metabolic biomarkers of MDR-TB, as alternative diagnostic options in future. Decreased NADH metabolites, phosphatidylcholines, caprylic acid, and increased D-xylulose in serum distinguished MDR-TB patients from drug-susceptible TB patients and healthy controls.…”

Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug‐resistant tuberculosis based on data‐independent acquisition and targeted proteomics

“…For smear‐negative detection, most (68%) Chinese smear‐negative TB patients were given diagnostic treatment (the treatment is effective) without drug resistance test or bacteriological confirmation, leading to a increased risk of excessive side‐effects, drug resistance and decreased drug efficacy. Furthermore, only approximately 1.6% of Chinese TB patients reported were rifampin‐resistant, leaving more than 80% of cases undetected 6,7 …”

“…Furthermore, only approximately 1.6% of Chinese TB patients reported were rifampin-resistant, leaving more than 80% of cases undetected. 6,7 There are two main diagnostic methods for MDR-TB. One is based on culture phenotypes, such as Drug Susceptibility Testing (DST), which is the principal standard for the diagnosis of MDR-TB.…”